title: Hydrodynamics-based delivery of the viral interleukin-10 gene suppresses experimental crescentic glomerulonephritis in Wistar-Kyoto rats.
abstract: Gene therapy is expected to revolutionize the treatment of kidney diseases. Viral interleukin (vIL)-10 has a variety of immunomodulatory properties. We examined the applicability of vIL-10 gene transfer to the treatment of rats with crescentic glomerulonephritis, a T helper 1 (Th 1) predominant disease. To produce the disease, Wistar-Kyoto rats were injected with a rabbit polyclonal anti-rat glomerular basement membrane antibody. After 3 h, a large volume of plasmid DNA expressing vIL-10 (pCAGGS-vIL-10) solution was rapidly injected into the tail vein. pCAGGS solution was similarly injected into control rats (pCAGGS rats). We confirmed the presence of vector-derived vIL-10 mainly in the liver and observed high serum vIL-10 levels in pCAGGS-vIL-10-injected rats. Compared with the pCAGGS rats, the pCAGGS-vIL-10 rats showed significant therapeutic effects: reduced frequency of crescent formation, decrease in the number of total cells, macrophages, and CD4+ T cells in the glomeruli, decrease in urine protein, and attenuation of kidney dysfunction. Using quantitative real-time polymerase chain reaction, we also observed that this model was Th1-predominant in the glomeruli and that the ratio of the transcripts of CD4, interferon-gamma, tumor necrosis factor-alpha, and monocyte chemotactic protein-1 to the transcripts of glucose-6-phosphate dehydrogenase in the glomeruli were all significantly lower in the pCAGGS-vIL-10 rats than in the pCAGGS rats. These results demonstrate that pCAGGS-vIL-10 gene transfer by hydrodynamics-based transfection suppresses crescentic glomerulonephritis.
authors.affiliation: Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Higuchi
authors.forename: H
authors.initials: H
authors.lastname: Maruyama
authors.forename: T
authors.initials: T
authors.lastname: Kuroda
authors.forename: S
authors.initials: S
authors.lastname: Kameda
authors.forename: N
authors.initials: N
authors.lastname: Iino
authors.forename: H
authors.initials: H
authors.lastname: Kawachi
authors.forename: Y
authors.initials: Y
authors.lastname: Nishikawa
authors.forename: H
authors.initials: H
authors.lastname: Hanawa
authors.forename: H
authors.initials: H
authors.lastname: Tahara
authors.forename: J
authors.initials: J
authors.lastname: Miyazaki
authors.forename: F
authors.initials: F
authors.lastname: Gejyo
mesh_terms: D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018932:Chemokine CCL2 / Q000378:metabolism; D004247:DNA / Q000008:administration & dosage; D015316:Genetic Therapy / Q000379:methods*; D005921:Glomerulonephritis / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D005954:Glucosephosphate Dehydrogenase / Q000378:metabolism; D007275:Injections, Intravenous; D007371:Interferon-gamma / Q000276:immunology; D016753:Interleukin-10 / Q000032:analysis / Q000235:genetics*; D007668:Kidney / Q000276:immunology* / Q000378:metabolism; D008099:Liver / Q000276:immunology / Q000378:metabolism; D008264:Macrophages / Q000276:immunology; D008297:Male; D023421:Models, Animal; D011817:Rabbits; D051381:Rats; D011921:Rats, Inbred WKY; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018417:Th1 Cells / Q000276:immunology; D014161:Transduction, Genetic / Q000379:methods*
chemical_list: D018932:Chemokine CCL2; D016753:Interleukin-10; D007371:Interferon-gamma; D004247:DNA; D005954:Glucosephosphate Dehydrogenase